Evaluation of effects of topical estradiol benzoate application on cutaneous wound healing in ovariectomized female mice by Mukai Kanae et al.
Evaluation of effects of topical estradiol
benzoate application on cutaneous wound
healing in ovariectomized female mice
著者 Mukai Kanae, Urai Tamae, Asano Kimi, Nakajima
Yukari, Nakatani Toshio










Creative Commons : 表示 - 非営利 - 改変禁止
http://creativecommons.org/licenses/by-nc-nd/3.0/deed.ja
RESEARCH ARTICLE
Evaluation of Effects of Topical Estradiol
Benzoate Application on CutaneousWound
Healing in OvariectomizedFemale Mice
Kanae Mukai1*, Tamae Urai2, Kimi Asano2, Yukari Nakajima2, Toshio Nakatani1
1 Faculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa
University, Kanazawa, Japan, 2 Department of Clinical Nursing, Graduate Course of Nursing Science,
Division of Health Sciences, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
* kanae_m@staff.kanazawa-u.ac.jp
Abstract
Estrogen promotes cutaneous wound healing in ovariectomized (OVX) female mice. How-
ever, the effects of topical estrogen application on wounds remain unclear. Therefore, the
aim of this study was to compare the effects of topical estrogen application on wounds with
standard treatment methods. Eight-week-old C57BL/6J female mice underwent OVX and
received two full-thickness wounds four weeks later. Mice were divided into three groups:
topical estradiol benzoate (EB) (0.75 μg/g/day) wound treatment, subcutaneous estradiol
(E2) pellets (0.05 mg, 21 days), and topical E2 (0.01 g/day) skin application. Wound healing
was observed until day 14. Wound area ratios were significantly smaller in the topical EB
wound treatment group than in the subcutaneous E2 pellet group on days 1–14 (p < 0.05)
and topical E2 skin application group on days 1–9 (p < 0.05). Neutrophil and macrophage
numbers were significantly smaller in the topical EB wound treatment group than in the sub-
cutaneous E2 pellet and topical E2 skin application groups on day 7 (p < 0.05). Moreover,
the number of new blood vessels and ratio of myofibroblasts were significantly larger in the
topical EB wound treatment group than in the subcutaneous E2 pellet and topical E2 appli-
cation skin groups on day 7 (p < 0.05). These results demonstrate that the application of
estrogen to wounds reduced inflammatory responses and promoted angiogenesis and
wound contraction more than the two other standard treatment methods.
Introduction
Cutaneous wound healing is a complex and tightly orchestrated response to injury, is carefully
regulated at temporal and spatial levels [1], and involves three major stages: inflammation, pro-
liferation, and remodeling.However, various factors play roles in cutaneous wound healing
[2]. Recent studies reported that female sex hormones, in particular estrogen, affect cutaneous
wound healing. Estrogen is the predominant steroid responsible for secondary sexual charac-
teristics in girls and women and influences the function of all major organ systems within the
body [3], and the ovary is the major source of estrogen production in the premenopausal
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period.Although estrogen is synthesized in steroidogenic cells of the ovary, estrogen is also
synthesized in the skin. As the estrogen product decreases after the menopause, the skin is an
important site of estrogen production [4]. However, in menopausal women, cutaneous wound
healing was shown to be delayed and inflammatory responses prolonged followingmarked
reductions in estrogen [5, 6]. These studies indicated that estrogen production in the skin is
not sufficient to maintain cutaneous wound healing. Since delayed cutaneous wound healing
increases health service costs [7], available treatments need to be performed in order to pro-
mote cutaneous wound healing.
One of these treatments, the application of estrogen is receiving increasing attention. Previ-
ous studies reported that the systemic administration of hormone replacement therapy (HRT)
to menopausal women reversed delayed cutaneous wound healing [5], while the topical
replacement of estrogen in healthy aged individuals reversed delayed cutaneous wound healing
[6]. Therefore, in order to clarify the effects of estrogen on cutaneous wound healing, an ovari-
ectomized (OVX) female rodent model is used and animal research has been performed. The
administration of estrogen has been shown to promote cutaneous wound healing in 8-
12-week-old OVXmice by decreasing neutrophil and macrophage numbers as well as the
expression of TNF-α [8–13], by increasing Ym1-positive cell numbers [11] and the expression
of TGF-β1 [5, 12], and by promoting collagen deposition [6, 9]. Moreover, we have evaluated
the effects of estrogen on cutaneous wound healing upon delayed cutaneous wound healing
using several OVX mice models. Our previous findings demonstrated that the administration
of estrogen promoted cutaneous wound healing in 24- and 40-week-old OVXmice by reducing
neutrophil and macrophage numbers and promoting re-epithelialization, collagen deposition,
and wound contraction [14, 15]. We also recently reported that the administration of estrogen
promoted the appearance of anti-inflammatoryM2-like macrophages in protein malnutrition
OVXmice [16].
In our previous studies, OVX mice were treated with the topical application of a 17β-estra-
diol (E2) gel (L’estrogel 0.06%; Bayer Yakuhin, Osaka, Japan) to the skin on the back, avoiding
the wounds, every day after wounding [14–16]. In other studies, OVXmice were administrated
a 0.05-mg, 21-d, slow-release E2 pellet (Innovative Research of America, Sarasota, FL) at the
time of wounding by s.c. implantation [8–13, 17–21]. Many external agents have been applied
to wounds and their effects on cutaneous wound healing have been evaluated [22–27]. How-
ever, the effects of topical estrogen application on wounds currently remain unclear. We
hypothesized that the topical application of estrogen to wounds promotes cutaneous wound
healingmore than other standard treatment methods involving topical skin and subcutaneous
applications. Therefore, the aim of the present study was to compare the effects of the topical
application of estrogen on wounds with standard treatment methods in OVXmice.
Materials and Methods
Animals
Eighty-five C57BL/6 female mice aged 7 weeks (Sankyo Lab ServiceCo., Tokyo, Japan) were
used in experiments. They were caged individually in an air-conditioned room at 25.0 ± 2.0°C
with lights on from 08:45 to 20:45, and water and chow were given freely. All animal experi-
ments conducted in this study were reviewed and approved by the Kanazawa University Ani-
mal Experiment Committee, and carried out in accordance with the Guidelines for the Care
and Use of Laboratory Animals of Kanazawa University, Japan (AP-153483). Mice were accli-
mated for 7 days before the initiation of surgery. At 8 weeks, mice were anesthetized by inhala-
tional anesthesia using 1.5% isoflurane (Wako, Tokyo, Japan) in 1.5 L O2/min over a plastic
tube mask and the dorsum was shaved. They then underwentOVX according to the OECD
Effects of EB on Wound Healing in OVX Mice
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guidelines [28] under inhalational anesthesia using 2.5% isoflurane. They were divided into
three groups: a topical estradiol benzoate (EB) wound treatment group, subcutaneous estradiol
(E2) pellet group, and topical E2 skin application group.
Wounding
At 12 weeks (4 weeks after surgery), under anesthesia with shaving, two circular full-thickness
skin wounds (4 mm in diameter) including the panniculus carnosus muscle were made on
both sides of the dorsum of the mouse with a Kai sterile disposable biopsy punch (Kai Indus-
tries Co. Ltd., Gifu, Japan). The wounds were covered with a hydrocolloid dressing (Tegaderm;
3M Health Care, Tokyo, Japan) to maintain a moist environment, and the mouse was then
wrapped with sticky bandages (SkinergateTM; Nichiban, Tokyo, Japan), which were changed
every day.
Exogenous estrogen administration
In the topical EB wound treatment group, EB (Estra-1,3,5(10)-triene-3,17β-diol 3-benzoate)
(OVAHORMON1INJECTION; ASKA Pharmaceutical Co. Ltd., Tokyo, Japan) was applied at
0.75 μg/g/day to the wounds every day after wounding. EB was diluted at 0.75 μg/g in sesame
oil (Wako Pure Chemical Industries Ltd., Tokyo, Japan). In the subcutaneous E2 (Estra-1,3,5
(10)-triene-3,17β-diol) pellet group, a 0.05-mg, 21-d, slow-release E2 pellet (Innovative
Research of a America, Sarasota, FL) was administrated at the time of wounding by s.c. implan-
tation according to previous studies [8–13, 17–21]. In the topical E2 skin application group, E2
gel (L’estrogel 0.06%; Bayer Yakuhin, Osaka, Japan) was applied at 0.01 g/day to the skin on
the back, avoiding the wounds, every day after wounding according to our previous studies
[14–16]. The dose administered was selectedwith successful estrogen replacement confirmed
by an enzyme immunoassay on plasma samples, vaginal smears, or uterine weights.
Macroscopic observations
The day when wounds were made was designated as day 0, and the process of wound healing
was observed from then until day 14 after wounding.Wound edges were traced on polypropyl-
ene sheets and photographs were taken every day. The traces on the sheets were captured with
a scanner onto a personal computer using Adobe Photoshop Elements 11.0 (Adobe System
Inc., Tokyo, Japan), and the areas of wounds were calculated using the image analysis software
ImageJ (National Institutes of Health, Bethesda,Maryland, USA). The wound area is shown as
the ratio of the wound area every day to the initial wound area on day 0 when the wound was
made, according to our previous studies [14–16].
Uterus assay and enzyme immunoassay analysis of 17β-estradiol (E2)
Mice were euthanized by an overdose of pentobarbital sodium administered i.p. on days 3, 7
11, and 14. The uterus was harvested according to the OECD guidelines [28] and its wet weight
was measured using a precision balance (d = 0.001 g) on days 3–14. In the additional three
OVXmice, the uterus was harvested, and the effects of estrogen administration were examined
in the in topical EB wound treatment, subcutaneous E2 pellet, and topical E2 skin application
groups. Plasma was prepared from each mouse’s blood, isolated through cardiac puncture, and
frozen until the time of assay. Enzyme immunoassay analysis (EIA) was performed to deter-
mine the concentration of E2 in the plasma on day 14, according to manufacture’s instruction
(KGE014, R&D systems Inc., Tokyo, Japan).
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Histological procedure
Mice were euthanized by an overdose of pentobarbital sodium administered i.p. on days 3, 7,
11, and 14 after wounding. The wound and surrounding intact skin were harvested and each
wound and surrounding intact skin sample was bisected at the wound center. One-half of each
wound was stapled onto polypropylene sheets to prevent over-contraction of the sample and
fixed in 4% paraformaldehyde for 17 hours. Samples were dehydrated in an alcohol series,
cleaned in xylene, and embedded in paraffin to prepare 5-μm-thick serial paraffin sections. The
remainder of each wound was embedded in tissue-Tek OCT (Sakura Finetek, Japan) before fix-
ing to prepare 5-μm-thick serial ice sections. At least 3 serial paraffin sections and 2 serial ice
sections near the center of the wound were obtained from one wound and stained according to
the followingmethods. Five-μm-thick paraffin sections were subjected to hematoxylin and
eosin (H&E) staining and immunohistologically stained with an anti-neutrophil antibody at a
concentration of 1:100 (ab2557, Abcam Japan, Tokyo, Japan) to detect neutrophils and an
anti-Mac-3 antibody at a concentration of 1:100 (550292, BD Pharmingen, Tokyo, Japan) to
detect macrophages. Five-μm-thick ice sections were immunohistologically stained with an
anti-α smooth muscle actin (α-SMA) antibody at a concentration of 1:300 (ab5694, Abcam
Japan, Tokyo, Japan) to detect myofibroblasts and an anti-CD31 antibody at a concentration of
1:50 (550274, BD Pharmingen, Tokyo, Japan). Negative control slides were obtained by omit-
ting each primary antibody. Immunohistological staining was performed as described below.
Immunohistological staining
On paraffin sections, after deparaffinization and rehydration, antigen retrieval was achieved
with SodiumCitrate Buffer (10 mM sodium citrate, 0.05% Tween20, pH 6.0) at approximately
100°C for 20 minutes. Endogenous peroxidase activity was blocked by 3% H2O2. Slides for an
anti-mouse Mac-3 antibody were washed with phosphate-buffered saline (PBS), and slides for
an anti-neutrophil antibody were washed with 0.3% Triton X-100 in PBS. Slides were then
incubated with an anti-neutrophil antibody or Mac-3 antibody at a concentration of 1:100 in
PBS at 4°C overnight. Slides were again washed. In order to detect primary antibodies, slides
for the anti-mouseMac-3 and anti-neutrophil antibodies were incubatedwith polyclonal rabbit
anti-rat immunoglobulins/HRP (Dako North America, California, USA) at a concentration of
1:300 in 0.3%mouse serum (normal) (Dako North America, California, USA) in PBS at 4°C
for 30 minutes. Slides were again washed, incubated in the Dako Liquid DAB+ Substrate Chro-
mogen System (Dako North America, California, USA) for 5 minutes or until staining was
detected at room temperature, and then counterstained with hematoxylin for 1 minute. All
slides were rinsed in distilledwater, dehydrated, cleared, and mounted for analyses.
On cryosections, 5-μm-thick sections were cut and fixed for 15 minutes in ice-cold acetone.
In slides for the anti-α-SMA antibody, endogenous peroxidase activity was blocked by 0.3%
H2O2 and slides were washed with 0.05% Tween-20 in PBS. Slides were then incubated with
the anti-α-SMA antibody at a concentration of 1:500 in PBS at room temperature for 1 hour.
Slides were again washed. In order to detect the primary antibody, slides for the anti-α-SMA
antibody were incubated with the Dako Envision+ system HRP-labeled polymer anti-rabbit
(ready to use) (Dako North America, California, USA) at room temperature for 30 minutes.
Slides were again washed, incubated using the Dako Liquid DAB+ Substrate Chromogen Sys-
tem for 5 minutes or until staining was detected at room temperature, and then counterstained
with hematoxylin for 1 minute. All slides were rinsed in distilledwater, dehydrated, cleared,
and mounted for analyses. Slides were incubated with the anti-CD31 antibody at a concentra-
tion of 1:50 in TBS at room temperature for 1 hour. Slides were washed with TBS. In order to
detect the primary antibody, slides for the anti-CD31 antibody were incubated with goat
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polyclonal to Rat IgG-H&L (AP) (Abcam Japan, Tokyo, Japan) at room temperature for 2
hours. Slides were again washed, incubated using the BCIP/NBT substrate system (Dako
North America, California, USA) for 10 minutes or until staining was detected at room tem-
perature, and counterstained with methyl green for 1 minute. All slides were rinsed in distilled
water and mounted for analyses.
Microscopic observations
Images were imported onto a computer using a digital microscopic camera (DP2-BSWOlym-
pus, Japan). In order to analyze neutrophil and macrophage numbers in the wound area, each
positive cell was counted using the image analysis software ImageJ with a x40 objective at five
sites of the wound: two sites near the two wound edges and three sites around the center of the
wound. The areas of these five sites were calculated on the monitor of DP2-BSW and the total
numbers of neutrophils and macrophages at the five sites were divided by the whole area of
these five sites. In order to analyze the numbers of new blood vessels in granulation tissue, each
new blood vessel was counted using the image analysis software ImageJ with a x20 objective at
five sites of granulation tissue: two sites near the two wound edges and three sites around the
center of the granulation tissue. The total number of new blood vessels at the five sites was
divided by the total area of these five sites. The number of blood vessels in normal skin was the
same as that analyzed above. Measurements of brown-colored myofibroblasts (myofibroblast
pixels/total wound pixels) were performed using Adobe Photoshop Elements 11.0, according
to our previous studies [14–16].
Statistical analysis
Data are expressed as the mean ± SD and analyzed using JMP1 12.1.0 (SAS Institute Inc.,
Cary, NC, USA). Comparisons of means among multiple groups were performedwith a one-
way ANOVA followed by post hoc pairwise comparisons using the Tukey-Kramer multiple
comparison test. P< 0.05 was considered significant.
Results
Uterine weights and 17β-estradiol (E2) value
We confirmed that the ovaries had been successfully removed in all groups. At each time point,
uterine weight was significantly larger in the three groups than in OVXmice (p< 0.01). After
the administration of estrogen, uterine weights in the three groups gradually increased until
day 14 after wounding. Uterine weights increasedmore rapidly on day 3 in the topical EB
wound treatment group than in the two other groups, and were also significantly larger in the
topical EB wound treatment group than in the subcutaneous E2 pellet and topical E2 skin
application groups on day 3 (p< 0.01) (Fig 1). On day 14, E2 value was 54.9±38.5 pg/mL in
the topical EB wound treatment group, 38.1±20.6 pg/mL in the subcutaneous E2 pellet group,
and 12.0±1.3 pg/mL in the topical E2 skin application group.
Wound area
In the subcutaneous E2 pellet and topical E2 skin application groups, wound areas increased
for 5 days and then rapidly decreased until day 11, after which they decreased gradually until
day 14 (ratio of the wound area to the initial wound area on day 14: 0.11 ± 0.07 in the subcuta-
neous E2 pellet group and 0.10 ± 0.06 in the topical E2 to the skin group). On the other hand,
in the topical EB wound treatment group, wound areas only increased for 1 day and then rap-
idly decreased until day 9, after which they decreased gradually until day 14 (0.04 ± 0.03). The
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wound area ratio was significantly smaller in the topical EB wound treatment group than in
the subcutaneous E2 pellet group on days 1–14 (p< 0.05) and topical E2 skin application
group on days 1–9 (p< 0.05) (Fig 2A and 2B).
Neutrophils and macrophages
A large number of neutrophils was observed in wounds in all groups on day 3 and then rapidly
decreased until day 7, particularly in the topical EB wound treatment group. The number of
neutrophils was significantly smaller in the topical EB wound treatment group than in the sub-
cutaneous E2 pellet and topical E2 skin application groups (p< 0.05) (Fig 3A and 3C).
A large number of macrophages was also observed in wounds in all groups on day 3 and
then decreased until day 7. The number of macrophages was also significantly smaller in the
topical EB wound treatment group than in the subcutaneous E2 pellet and topical E2 skin
application groups (p< 0.05) (Fig 3B and 3C).
Angiogenesis and wound contraction
In the topical EB wound treatment group, many new blood vessels were observed in granula-
tion tissue on day 7 and gradually decreased in number from days 7 to 14. On the other hand,
in the subcutaneous E2 pellet and topical E2 skin application groups, new blood vessels were
observed in granulation tissue on day 7, they increased in number until day 11, and then
decreased in number until day 14. The number of new blood vessels was significantly larger in
the topical EB wound treatment group than in the subcutaneous E2 pellet and topical E2 skin
application groups on day 7 (p< 0.05). Otherwise, the number of blood vessels in normal skin
was the same in all groups on days 7 to 14 (Fig 4A and 4C).
Fig 1. Uterine weight. Uterine weights are shown in box graphs. Values are expressed as the mean ± SD,
n = 5–7 for each group, ANOVA, Tukey-Kramer *p<0.05 (in black): the topical EB wound treatment group
versus the subcutaneous E2 pellet group, *p<0.05 (in red): the topical EB wound treatment group versus the
topical E2 skin application group, ☨p<0.05: versus OVX.
doi:10.1371/journal.pone.0163560.g001
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In the topical EB wound treatment group, a large number of myofibroblasts was observed in
granulation tissue on day 7 that formed bridge-like structures across the wound, and gradually
decreased in number from days 7 to 14. On the other hand, in the subcutaneous E2 pellet and
topical E2 skin application groups, myofibroblasts were observed in granulation tissue on day
7, increased in number until day 11, formed bridge-like structures across the wound, and then
decreased in number until day 14. The ratio of myofibroblasts was significantly larger in the
topical EB wound treatment group than in the subcutaneous E2 pellet and topical E2 skin
application groups on day 7 (p< 0.05) (Fig 4B and 4C).
Discussion
In the present study, we compared the effects of the topical application of estrogen on wounds
with two other standard treatment methods. According to our hypothesis, cutaneous wound
healing is promoted more by the effects of the topical application of estrogen to wounds than
by the two other standard methods, namely, topical application to the skin on the back, avoid-
ing the wounds [14–16], and the subcutaneous administration of a pellet at the time of wound-
ing by s.c. implantation [8–13, 17–21]. Wound area ratios were significantly smaller in the
topical EB wound treatment group than in the subcutaneous E2 pellet group on days 1–14 and
topical E2 skin application group on days 1–9. This result shows that the topical application of
Fig 2. Macroscopic wound healing. (A) Wounds that were 4 mm in diameter were inflicted and healing
was recorded by photography. Bar, 5 mm. (B) Ratios of wound areas to the initial area on day 0 are shown on
line graphs for each day. Values are expressed as the mean ± SD, n = 10, ANOVA, Tukey-Kramer *p<0.05
(in black): the topical EB wound treatment group versus the subcutaneous E2 pellet group, *p<0.05 (in red):
the topical EB wound treatment group versus the topical E2 skin application group.
doi:10.1371/journal.pone.0163560.g002
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Fig 3. Neutrophils and macrophages. (A) The number of neutrophils per mm2 and (B) number of macrophages per mm2 are
shown in box graphs. Values are expressed as the mean ± SD, n = 5–6 for each group, ANOVA, Tukey-Kramer *p<0.05 (in
black): the topical EB wound treatment group versus the subcutaneous E2 pellet group, *p<0.05 (in red): the topical EB wound
treatment group versus the topical E2 skin application group. (C) Neutrophils (arrows) stained with an anti-neutrophil antibody
and macrophages (arrows) stained with an anti-Mac-3 antibody were observed in wound tissue on day 7. Bar, 20 μm.
doi:10.1371/journal.pone.0163560.g003
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Fig 4. New blood vessels and wound contraction. (A) The number of new blood vessels per mm2 and (B) ratio of
myofibroblasts (%) are shown in box graphs. Values are expressed as the mean ± SD, n = 5–6 for each group, ANOVA, Tukey-
Kramer *p<0.05 (in black): the topical EB wound treatment group versus the subcutaneous E2 pellet group, *p<0.05 (in red): the
topical EB wound treatment group versus the topical E2 skin application group. (C) New blood vessels stained with an anti-CD31
antibody (bars, 50 μm) and myofibroblasts (arrows) stained with an anti-α-SMA antibody (bars, 200 μm) were observed in
granulation tissue on day 7.
doi:10.1371/journal.pone.0163560.g004
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estrogen to wounds reduced the wound area more than the two other standard methods during
the whole process of healing. The effects of the topical application of estrogen to wounds may
be related to early increases in uterine weights. Uterine weights were significantly larger in the
topical EB wound treatment group than in the subcutaneous E2 pellet and topical E2 skin
application groups on day 3. Successful estrogen replacement was confirmed by a gain in uter-
ine weight [14–16]. Therefore, early successful estrogen replacement by the topical application
of estrogen to wounds may be responsible for the effects observed.
The wound area did not increase in the inflammatory phase by the topical application of
estrogen to wounds. The inflammatory phase is regarded as a critical period in cutaneous
wound healing that is essential for clearing contaminating bacteria and creating an environ-
ment that is conducive to subsequent events involved in tissue repair and regeneration [29–
31]. In the present study, the wound area only increased for 1 day in the topical EB wound
treatment group, but increased for 5 days in the subcutaneous E2 pellet and topical E2 skin
application groups. We previously demonstrated that cutaneous wound healing involves
increases in the wound area in the inflammatory phase followed by gradual decreases [14–16,
26, 27]. Moreover, as an evaluation outcome of the inflammatory response, we also compared
the numbers of neutrophils and macrophages. Neutrophils and macrophages are mainly active
in the wound site in the inflammatory phase. Neutrophils prevent infection through phagocytic
processes and propagate the inflammatory response by releasing cytokines [31, 32], and macro-
phages exhibit antimicrobial properties by releasing inflammatory cytokines [33]. The num-
bers of neutrophils and macrophages in wounds in the inflammatory phase have been shown
to decrease in OVXmice administrated estrogen [8–13] and increases in the wound area in the
inflammatory phase were slightly reduced in OVX female mice administrated estrogen [14]
due to its anti-inflammatory effects [8–13]. In the present study, the numbers of neutrophils
and macrophages were also significantly smaller in the topical EB wound treatment group than
in the subcutaneous E2 pellet and topical E2 skin application groups on day 7. Therefore, these
results suggest that anti-inflammatory effects were more prominent due to the topical applica-
tion of estrogen to wounds than the two standard methods, resulting in a shorter inflammatory
response.
Although the mechanism underlying the decrease in the number of inflammatory cells in
cutaneous wound healing in the present study is still unknown, we hypothesize the cutaneous
immune system to be responsible. The cutaneous immune system is integrated into the cutane-
ous neuro-endocrine system [34] through interaction with multiple pro-inflammatory and
anti-inflammatory neuropeptides, cytokines, and hormones [35]. One component of the cuta-
neous neuro-endocrine system, the hypothalamic-pituitary-adrenal (HPA) axis, is fundamen-
tal as the body’s coordinator of responses to systemic and local stress [34, 36, 37]. At the local
HPA axis, cytokines serve as communicators between the immunological and neuro-endocrine
system, and a possible feedback loop in the HPA axis attenuates the initial pro-inflammatory
responses, preventing excess inflammation [36]. A recent study reported that ultraviolet radia-
tion (UV) exposure to the skin or skin cells enhanced cortisol production [38]. Furthermore, it
was also reported that UV exposure up-regulated expression of anti-inflammatory cytokines
[39], and these up-regulated anti-inflammatory cytokines also stimulated components of the
HPA axis to enhance cortisol production [40]. These findings suggest that an external factor,
such as UV exposure, can act as a trigger to activate the local HPA axis. Therefore, we speculate
that topical application of estrogen to wounds may act as an external factor in the cutaneous
neuro-endocrine system, similar to UV exposure, and prevent excessive inflammatory
response. Moreover, we focused on the intracellular response. Estrogen signals act via two
nuclear hormone receptors; estrogen receptor α (ER-α) and estrogen receptor β (ER-β) [36]. In
mice skin, both receptors are widely expressed [17]. Previous study has reported that estrogen
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replacement in inflammatory cell specific ER-α null OVXmice (LysM-ERα) elevated local neu-
trophils and influx excessive macrophages [20], and macrophage recruitment in acute and
chronic brain injury is mediated through ER-α [41]. It is also reported that estrogen replace-
ment in LysM-ER-α OVXmice increased iNOS and reduced Arg1 [20] and ER-α KO mice dis-
play increased levels of pro-inflammatory chemokines during neuro-inflammation [42]. These
studies suggest that inflammatory cell influx into the wound is mediated by estrogen signals via
ER-α, and that cytokines are involved. Thus, we hypothesize that reduction of inflammatory
cells after topical application of estrogen to wounds is mediated by estrogen signals via ER-α.
Further research is needed to confirm these our theory. Furthermore, the reason why there
were no significant differences between the topical application of estrogen to wounds and the
two other standard treatment methods on day 3 remains unclear. Therefore, we also need to
conduct further research in the near future.
Due to a shorter inflammatory response, wound contraction with the topical application of
estrogen to wounds in OVXmice occurred faster than that by the two other standard treatment
methods. In the present study, wound areas only increased for 1 day and then decreased rapidly
until day 9 in the topical EB wound treatment group, whereas wound areas increased for 5 days
and then decreased rapidly until day 11 in the subcutaneous E2 pellet and topical E2 skin appli-
cation groups. This result is consistent with those obtained from immunohistological staining
with the anti-α-SMA antibody. α-SMA is the most commonly usedmolecularmarker for myo-
fibroblasts [43] and α-SMA-positive myofibroblasts appear at the beginning of wound contrac-
tion and have intercellular adhesionmolecules such as gap junctions linking them to each
other [44–46]. In the present study, in the topical EB wound treatment group, many myofibro-
blasts were observed in granulation tissue on day 7, formed bridge-like structures across the
wound, and then gradually decreased from days 7 to 14. On the other hand, in the subcutane-
ous E2 pellet and topical E2 skin application groups, myofibroblasts were observed in granula-
tion tissue on day 7, increased in number until day 11, formed bridge-like structures across the
wound, and then decreased in number until day 14. Moreover, the ratio of myofibroblasts was
significantly larger in the topical EB wound treatment group than in the subcutaneous E2 pellet
and topical E2 skin application groups on day 7. The events of wound contraction during cuta-
neous wound healing occurred as follows; initial phase, starting phase, increasing phase,
decreasing phase, and scar phase [46]. In the starting phase, a fewmyofibroblasts appeared
along the wound edge, and contraction started to occur, but weakly. At the increasing phase, a
large number of myofibroblasts developed along the wound edge and wound bed, and formed
bridge-like structures across the wound. In this phase, wound contraction is the strongest. In
the decreasing phase, myofibroblast numbers in the wound bedmarkedly decreased, and, thus,
the bridge-like structure disappeared. In this phase, wound contraction gradually weakens.
Our results clearly show that the appearance of myofibroblasts in granulation tissue and forma-
tion of bridge-like structures occurred faster in the topical EB to wound treatment group than
in the subcutaneous E2 pellet and topical E2 skin application groups. Therefore, wound con-
traction appears to be promoted more by the topical application of estrogen to wounds than
the two other standard treatment methods.Moreover, with shortening of the inflammatory
response, angiogenesis caused by the topical application of estrogen to wounds in OVXmice
also occurred faster than the two other standard treatment methods. Estrogenmay decrease
vasoconstrictiondue to improvements in NOS signaling [47]. Functional impairments in the
ERα/NOS-3 signaling network in OVX diabetic animals were partially restored by the adminis-
tration of 17β-estradiol [48]. In an in vitro study, the capacity of endothelial cells for tube for-
mation decreased in the presence of a high concentration of glucose (30 mM) and was rescued
by a specific ERβ antagonist (PTHPT) [49]. These findings show that female sex hormones
play important roles in angiogenesis. In the present study, the number of new blood vessels
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was significantly larger in the topical EB wound treatment group than in the subcutaneous E2
pellet and topical E2 skin application groups on day 7. Therefore, angiogenesis appears to have
been promoted more by the topical application of estrogen to wounds than by the two other
standard treatment methods. These results indicate that the topical application of estrogen to
wounds promotes wound contraction and angiogenesis more than the two other standard
treatment methods.
In summary, we found that the topical application of estrogen to wounds reduced the
inflammatory response and promoted angiogenesis and wound contractionmore than the two
other standard treatment methods. Therefore, the topical application of estrogen to wounds is
the most suitable treatment method of estrogen on cutaneous wound healing in OVXmice.
We previously reported that the administration of estrogen promoted the appearance of anti-
inflammatoryM2-like macrophages in protein malnutrition OVXmice; however, it did not
promote cutaneous wound healing with a low-protein diet [16]. These findings suggest that the
administration of estrogen cannot promote cutaneous wound healing in malnutrition OVX
mice. However, more than 50% of the elderly in hospitals and institutions were reported to be
malnourished or at risk of malnutrition in developed countries [50, 51], and malnutrition has
been shown to increase in Japan as the level of required care becomes high [51]. Therefore, we
need to conduct further research in the near future in order to clarify whether the topical appli-
cation of estrogen to wounds promotes cutaneous wound healing in malnutrition OVXmice.
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